Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative

  title={Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative},
  author={Nicole Rodrigues Silva and Felipe V. Gomes and Miriam D. Fonseca and Raphael Mechoulam and Aviva Breuer and Thiago Mattar Cunha and Francisco Silveira Guimar{\~a}es},
  journal={Progress in Neuro-Psychopharmacology and Biological Psychiatry},
  • N. SilvaF. Gomes F. Guimarães
  • Published 3 October 2017
  • Biology, Medicine, Chemistry
  • Progress in Neuro-Psychopharmacology and Biological Psychiatry

The Cannabidiol Analog PECS-101 Prevents Chemotherapy-Induced Neuropathic Pain via PPARγ Receptors

PECS-101, a new fluorinated CBD analog, could represent a novel therapeutic alternative to prevent mechanical and cold allodynia induced by PTX potentially through the activation of PPARγ in macrophages.

Contribution of the Adenosine 2A Receptor to Behavioral Effects of Tetrahydrocannabinol, Cannabidiol and PECS-101

The hypothesis that CBD and PECS-101 can potentiate the cataleptic effects of THC in a manner consistent with increased endogenous adenosine signaling is supported.

Synthetic and Natural Derivatives of Cannabidiol.

This chapter analyzes the knowledge gained so far on CBD and its analogs specially focusing on its molecular targets and metabolic implications to provide novel approaches to improve the therapeutic prospects offered by this promising chemotype.

Endocannabinoid System Attenuates Oxaliplatin-Induced Peripheral Sensory Neuropathy Through the Activation of CB1 Receptors.

The modulation of the endocannabinoid system, through the CB1 receptor, attenuates the oxaliplatin-associated PNS and could be considered as a therapeutic target for controlling oxaliPlatin- associated neuropathy.

HU-910, a CB2 receptor agonist, reverses behavioral changes in pharmacological rodent models for schizophrenia

Behavioural and pharmacological effects of cannabidiol (CBD) and the cannabidiol analogue KLS‐13019 in mouse models of pain and reinforcement

The aim of the present study was to characterize the behavioural effects of KLS‐13019 compared to CBD and morphine in mouse models of CIPN, nociceptive pain and reinforcement.

Vapor inhalation of cannabidiol (CBD) in rats

The vapor-inhalation approach is a suitable pre-clinical model for the investigation of the effects of inhaled CBD after this route of administration produces hypothermia in rats, while i.p. injection does not at comparable plasma CBD levels.

Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age

CBD is an useful and promising molecule that may help patients with a number of clinical conditions and should bring important answers in the near future and support the translation of research findings to clinical settings.



Interactions between THC and cannabidiol in mouse models of cannabinoid activity

As the amount of CBD found in most marijuana strains in the US is considerably less than that of THC, these results suggest that CBD concentrations relevant to what is normally found in marijuana exert very little, if any, modulatory effects on CB1-receptor-mediated pharmacological effects of marijuana smoke.

Cannabidiol-Δ9-tetrahydrocannabinol interactions on acute pain and locomotor activity.

Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects

A synthesis of 3 fluorinated CBD derivatives is reported, one of which, 4'-F-CBD (HUF-101) (1), is considerably more potent than CBD in behavioral assays in mice predictive of anxiolytic, antidepressant, antipsychotic and anti-compulsive activity.

Safety and side effects of cannabidiol, a Cannabis sativa constituent.

In vivo and in vitro reports of CBD administration across a wide range of concentrations suggest controlled CBD may be safe in humans and animals, but further studies are needed to clarify reported in vitro and in vivo side effects.